BridgeBio announced positive top-line results from Propel 3: oral infigratinib produced a statistically significant increase in annualized height velocity in children with achondroplasia. The trial met its primary endpoint with an adjusted least‑squares mean treatment difference versus placebo, and the company plans regulatory discussions and submissions later this year. The trial reported both primary and supporting growth endpoints that, according to the company, exceed previous randomized results in the indication and compare favorably with existing injectable therapies. Safety signals were manageable; the firm disclosed transient phosphate elevations in a small number of patients. BridgeBio said it will pursue filing discussions with regulators and accelerate development in related skeletal disorders. The result adds to a recent run of pivotal wins in rare-disease programs and will likely trigger competitive dynamics with approved and near‑launch competitors.